Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) vs. Exemestane (AROMASIN) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy

Next Previous
X
Search
Trial Profile

A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) vs. Exemestane (AROMASIN) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fulvestrant (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EFECT
  • Sponsors AstraZeneca

    • Most Recent Events

    • 16 Jun 2020 Results, a pooled analysis of the phase III SoFEA and EFECT trials, published in the Clinical Cancer Research
    • 03 May 2019 Results assess the correlation between serum Thymidine kinase 1 and patient outcome (retrospective analysis) published in the European Journal of Cancer.
    • 05 Jun 2018 Results of a retrospective analysis (n=244) assessing the role of serum thymidine kinase-1 (TK1) activity in HR+ advanced breast cancer using serum samples of patients from this study cohort, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top